

**Date: 21.05.2026**

To,  
**BSE Limited**  
The Compliance Department of Corporate Services,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

**Scrip Code: 531592**

**Subject: Outcome of the Meeting of Board of Directors held on Thursday, May 21, 2026.**

Dear Sir/ Madam,

With reference to the captioned subject and Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Board of Directors of the Company at its meeting held on today, i.e. Thursday, May 21, 2026, inter alia, considered and approved:

1. Considered and approved the Audited (Standalone and Consolidated) Financial Results of the Company for the quarter and year ended March 31, 2026 together with Report of Statutory Auditors as duly reviewed and recommended by the Audit Committee.

The declaration that the Report of the Statutory Auditors is with unmodified opinion with respect to Standalone & Consolidated Audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2026 is attached herewith.

2. The Re-appointment of M/s. Abhishek M Agrawal & Co., Chartered Accountant as Internal Auditor of the Company pursuant to Section 138 of the Company Act, 2013 and rules made there under for the financial year 2026-2027.

Pursuant to Regulation 33 of SEBI Listing Regulations, we enclose herewith the Audited Standalone & Consolidated Financial Results for the quarter and year ended March 31, 2026 along with Statement of Assets and Liabilities as on March 31, 2026 and Cash Flow Statement & Segment Report for the year ended March 31, 2026 and Auditors Reports thereon.

Disclosures as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is given in enclosed **Annexure A**.



# GENPHARMASEC LIMITED

The Board Meeting commenced at 4:30 p.m. today and concluded at 05:15 p.m.

Kindly take the same on records for your perusal.

Thanking you,

Yours faithfully,

For and behalf of the Board of Director of,  
**Genpharmasec Limited**

SOHAN  
CHATURVEDI

Digitally signed by  
SOHAN CHATURVEDI  
Date: 2026.05.21  
17:16:52 +05'30'



**Mr. Sohan Chaturvedi**  
**Whole time director & CFO**  
**DIN- 09629728**

**Encl.:** As above



104 & 105, 1st Floor, Gundecha Industrial Premises Co-Operative Soc  
Ltd., Akurli Road, Kandivali (East), Mumbai 400101.



+91-86555 50242



compliance@genpharmasec.com  
info@genpharmasec.com



www.genpharmasec.com

**ANNEXURE A**

Appointment of M/s. Abhishek M Agrawal & Co., Chartered Accountants, as the Internal Auditor of the Company:

<b>Sr. No.</b>	<b>Particulars</b>	<b>Disclosures</b>
1.	Name of the Internal Auditor	M/s. Abhishek M Agrawal & Co.
2.	Reason for change viz. appointment, reappointment, resignation, removal, death or otherwise	Following the provisions of Section 138 of the Companies Act, 2013 read with Rule 13 of the Companies (Accounts) Rules, 2014 and other applicable provisions (if any) of the Companies Act, 2013 the Company has appointed an Internal Auditor for conducting Internal Audit of the Company.
3.	Date of appointment / re-appointment / cessation (as applicable) & term of appointment / reappointment	May 21, 2026  Appointed for conducting an internal audit of the functions and activities of the Company for the Financial Year 2026-27.
4.	Brief profile	M/s. Abhishek M Agrawal & Co, Chartered Accountants are a Proprietary firm, established in 2017. Mr. Abhishek Agrawal is a seasoned Chartered Accountant with a specialization in taxation & Audits. With over 9 years of experience in the field, Abhishek has established himself as a trusted advisor in navigating complex tax regulations and optimizing tax strategies for individuals and businesses alike. He possesses a comprehensive understanding of Income Tax Act, GST Act, Customs and international tax laws and stays updated on the latest changes and developments in the taxation landscape.
5.	Disclosure of relationships between directors	Not Applicable

**Date: 21.05.2026**

To,  
**BSE Limited**  
The Compliance Department of Corporate Services,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

**Scrip Code: 531592**

Dear Sir/ Madam,

**Subject: Declaration pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (LODR) Regulations, 2015.**

In terms of provision of Regulation 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, we hereby declare that the Statutory Auditors of the Company M/s. Bilimoria Mehta & Co., Chartered Accountants, have issued an Audit Report with Unmodified Opinion on Standalone & Consolidated Audited Financial Results of the Company for the Quarter and Financial year ended 31<sup>st</sup> March, 2026.

Kindly take the same on records for your perusal.

Thanking you,

Yours faithfully,

For and behalf of the Board of Director of,  
**Genpharmasec Limited**

SOHAN  
CHATURVEDI

Digitally signed by  
SOHAN CHATURVEDI  
Date: 2026.05.21  
17:17:15 +05'30'



**Mr. Sohan Chaturvedi**  
**Whole time director & CFO**  
**DIN- 09629728**

**Independent Auditor's Report on Standalone Annual Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Genpharmasec Limited.**

**Opinion**

We have audited the accompanying standalone annual financial results ('the Statement') of **Genpharmasec Limited** ('the Company') for the year ended **March 31, 2026**, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended) ('Listing Regulations'), including relevant circulars issued by the SEBI from time to time.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

(i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations, and

(ii) gives a true and fair view in conformity with the applicable Indian Accounting Standards ('IndAS') prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with relevant rules issued thereunder, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company for the year ended March 31, 2026.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under Section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.

**Responsibilities of Management and Those Charged with Governance for the Statement**

This Statement has been prepared on the basis of the standalone annual audited financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the standalone net profit or loss and other comprehensive income and other financial information of the Company in accordance with the accounting principles generally accepted in India, including Ind AS prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds



and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation, and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Statement**

Our objectives are to obtain reasonable assurance about whether the standalone annual financial statement as a whole is free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under Section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place adequate internal financial controls with reference to financial statements and the operating effectiveness of such control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management and Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



- Evaluate the overall presentation, structure, and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to express an opinion on the Standalone Financial Results.

Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Other Matter Paragraph**

We draw attention to the fact that during the year ended March 31, 2026, the Company has carried out an impairment assessment in respect of its investments in Derren Healthcare Private Limited and Clinigenome India Private Limited, both being loss-making entities, in accordance with Ind AS 36 - Impairment of Assets. The said assessment was carried out basis a valuation report obtained from a Registered Valuer as defined under the Companies Act, 2013. Based on the aforesaid valuation, the recoverable amount of the said investments exceeds their carrying amount and accordingly, no impairment loss is required to be recognised in respect of the aforesaid investments as at March 31, 2026. Our opinion is not modified in respect of this matter.



The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations. Our opinion is not modified in respect of this matter.

The standalone financial results of the Company for the year ended March 31, 2025 were audited by erstwhile auditor of the Company who expressed an unmodified opinion on the standalone financial results vide their audit report dated May 21, 2025. Our opinion is not modified in respect of this matter.

**For Bilimoria Mehta & Co.**  
Chartered Accountants  
Firm Reg. No. 101490W



**CA Aakash Mehta**  
Partner  
Membership no. 165824  
UDIN: 26165824YYPIUA8203  
Place of Signature: Mumbai  
Date: May 21, 2026

**GENPHARMASEC LIMITED**  
Corporate Identity Number (CIN): L24231MH1992PLC323914  
Statement of Standalone Assets and Liabilities  
(All amounts are in INR Lakhs, unless otherwise stated)

Particulars	As at March 31, 2026 (Audited)	As at March 31, 2025 (Audited)	As at April 01, 2024 (Audited)
<b>ASSETS</b>			
<b>(1) Non-Current Assets</b>			
(a) Property, Plant and Equipments	10.77	9.11	10.16
(b) Right of Use Assets	101.91	27.02	-
(c) Financial Assets			
(i) Investments	2,167.02	2,083.76	1,909.72
(ii) Loans	2,456.98	2,896.46	1,207.22
(iii) Other Financial Assets	59.56	185.31	4.50
(d) Deferred Tax Assets (Net)	31.17	13.57	42.60
(e) Other Non-Current Assets	1.59	0.33	-
<b>Total Non-Current Assets</b>	<b>4,829.01</b>	<b>5,215.57</b>	<b>3,174.20</b>
<b>(2) Current Assets</b>			
(a) Inventories	1,257.81	724.43	758.19
(b) Financial Assets			
(i) Investments	-	-	168.39
(ii) Trade Receivables	2,801.57	1,338.61	909.99
(iii) Cash and Cash Equivalents	79.13	52.25	291.67
(iv) Bank Balances Other Than Cash And Cash Equivalents	850.00	462.12	1,566.20
(v) Loans	640.61	84.13	0.60
(vi) Other Financial Asset	411.97	9.81	32.31
(c) Other Current Assets	135.98	22.49	140.98
(d) Current Tax Asset	-	-	4.94
<b>Total Current Assets</b>	<b>6,177.08</b>	<b>2,693.83</b>	<b>3,873.26</b>
<b>Total Assets</b>	<b>11,006.09</b>	<b>7,909.40</b>	<b>7,047.46</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
(a) Equity Share Capital	5,537.20	5,537.20	5,537.20
(b) Other Equity	1,612.46	1,117.79	919.57
<b>Total Equity</b>	<b>7,149.66</b>	<b>6,654.99</b>	<b>6,456.77</b>
<b>LIABILITIES</b>			
<b>(1) Non-Current Liabilities</b>			
(a) Financial Liabilities			
(i) Borrowings	392.81	314.69	321.04
(ii) Lease Liabilities	77.43	13.95	-
(iii) Provisions	6.34	-	-
<b>Total Non-Current Liabilities</b>	<b>476.58</b>	<b>328.64</b>	<b>321.04</b>
<b>(2) Current Liabilities</b>			
(a) Financial Liabilities			
(i) Lease Liabilities	28.03	14.62	-
(ii) Trade Payables			
(A) Total outstanding dues of micro and small enterprises	26.90	16.64	11.73
(B) Total outstanding dues of creditors other than micro and small enterprises	2,985.68	801.88	226.06
(iii) Other Financial Liabilities	70.40	15.47	-
(b) Short Term Provisions	1.13	-	-
(c) Current Tax Liabilities	91.22	59.49	-
(d) Other Current Liabilities	176.50	17.66	31.86
<b>Total Current Liabilities</b>	<b>3,379.85</b>	<b>925.76</b>	<b>269.65</b>
<b>Total Equity and Liabilities</b>	<b>11,006.09</b>	<b>7,909.40</b>	<b>7,047.46</b>

For and on behalf of the Board of Directors of  
Genpharmasec Limited

*Sohan*

**GENPHARMASEC LIMITED**  
KANDIVALI  
MUMBAI  
400 101.

Place: Mumbai  
Date : May 21, 2026

Sohan Chaturvedi  
(Whole Time Director & CFO)  
DIN : 09629728

**GENPHARMASEC LIMITED**  
**Corporate Identity Number (CIN): L24231MH1992PLC323914**  
**Statement of Standalone Audited Financial Results for the Quarter and Year Ended March 31, 2026**  
**(All amounts are in INR Lakhs, unless otherwise stated)**

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31st March 2026	31st December 2025	31st March 2025	31st March 2026	31st March 2025
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from Operations	5,166.42	3,600.83	1,355.56	13,134.94	3,296.07
II	Other Income	161.79	142.89	106.05	486.94	343.09
III	<b>Total Income (I+II)</b>	<b>5,328.22</b>	<b>3,743.72</b>	<b>1,461.61</b>	<b>13,621.88</b>	<b>3,639.16</b>
IV	<b>Expenses</b>					
	Purchase of Stock-in-Trade	4,654.89	3,384.96	1,028.45	13,139.94	3,000.72
	Changes in Inventories of Finished goods, Stock-in-Trade and Work-in-progress	249.20	213.11	397.05	(533.38)	33.76
	Employee Benefit Expenses	24.62	22.46	17.66	97.27	66.81
	Finance Costs	24.75	19.09	5.98	59.36	27.75
	Depreciation and Amortization Expense	9.42	7.38	3.98	25.60	13.31
	Other Expenses	79.07	47.97	13.33	189.39	119.00
	<b>Total Expenses (IV)</b>	<b>5,041.94</b>	<b>3,694.95</b>	<b>1,466.44</b>	<b>12,978.19</b>	<b>3,261.35</b>
V	<b>Profit before Tax ( III- IV )</b>	<b>286.27</b>	<b>48.77</b>	<b>(4.84)</b>	<b>643.69</b>	<b>377.81</b>
VI	<b>Tax Expense :</b>					
	(1) Current Period	62.80	11.77	25.53	152.32	68.74
	(2) Deferred Tax	(8.34)	(2.77)	(6.39)	(17.73)	29.03
	(3) Prior Period Tax	-	(35.86)	-	(35.86)	-
	<b>Total Tax Expense</b>	<b>54.46</b>	<b>(26.87)</b>	<b>19.13</b>	<b>98.72</b>	<b>97.77</b>
VII	<b>Profit for the period ( V -VI )</b>	<b>231.81</b>	<b>75.64</b>	<b>(23.97)</b>	<b>544.96</b>	<b>280.04</b>
VIII	<b>Other Comprehensive Income</b>					
	A (i) Item that will not be reclassified to profit or loss					
	(a) Remeasurement of post employment defined benefit plans	0.52	-	-	0.52	-
	(b) Income tax effect on above	(0.13)	-	-	(0.13)	-
	(c) Equity instrument through other comprehensive income	(40.65)	(6.22)	(45.41)	(50.68)	(81.81)
	(d) Income tax effect on above	-	-	-	-	-
	<b>Sub-total</b>	<b>(40.26)</b>	<b>(6.22)</b>	<b>(45.41)</b>	<b>(50.29)</b>	<b>(81.81)</b>
IX	<b>Total Comprehensive Income for the period ( VII + VIII ) (Comprising profit and other comprehensive income for the year)</b>	<b>191.56</b>	<b>69.41</b>	<b>(69.38)</b>	<b>494.67</b>	<b>198.22</b>
	<b>Paid up Equity Share Capital ( Face Value of Equity Share is Rs. 1/- each )</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>
X	<b>Earnings per equity share:</b>					
	(1) Basic	0.04	0.01	(0.00)	0.10	0.05
	(2) Diluted	0.04	0.01	(0.00)	0.10	0.05

For and on behalf of the Board of Directors of  
Genpharmasec Limited

*Sohan*



Sohan Chaturvedi  
(Whole Time Director & CFO)  
DIN : 09629728

Place: Mumbai  
Date : May 21, 2026

**Notes to standalone audited financial results for the quarter and year ended March 31, 2026**

1. The audited financial results of the Company for the quarter and year ended March 31, 2026 have been prepared in accordance with the Indian Accounting Standards ("Indian Accounting Standards ("Ind As") As Prescribed under section 133 of the Companies Act, 2013 as amended.
2. The Company is primarily engaged in a single business segment in accordance with the requirements of Indian Accounting Standard (Ind AS) 108: *Operating Segments*. Accordingly, no separate segment information has been presented.
3. The audited financial results of the Company for the quarter and year ended March 31, 2026 have been reviewed by the audit committee on May 21, 2026 and thereafter Board of directors at their meeting held on May 21, 2026.
4. During the financial year, the Company reviewed its accounting policy relating to the classification and measurement of certain equity shares that were previously presented under Inventories. Upon a detailed evaluation of the nature and purpose of holding these shares, the management concluded that these instruments are held for investment purposes rather than for trading in the ordinary course of business.

Accordingly, during the current year, the Company has reclassified such shares from Inventories to Financial Investments in accordance with the requirements of Ind AS 109 - Financial Instruments and Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors. Consequently, these financial instruments are now measured at fair value through other comprehensive income (FVOCI) instead of being measured at the lower of cost and net realizable value under Ind AS 2 - Inventories.

The change in accounting policy has been applied retrospectively, and the financial impact of this reclassification for the period ended March 31, 2026, is as follows:

1. Decrease in Inventories: Rs. 89.32 Lakhs
  2. Increase in Investment (before impact of Fair value): Rs. 89.32 Lakhs
  3. Net Impact on Profit Before Tax: Nil
  4. Net impact on total comprehensive income: Rs. (22.66) Lakhs
5. During the year ended March 31, 2024, the Company entered into a Share Purchase Agreement (SPA) and a Share Subscription-cum-Shareholders Agreement (SSSA) on September 19, 2023 with M/s. Derren Healthcare Private Limited and its promoters for acquiring a 70% stake. The acquisition was completed on July 25, 2025, and accordingly, Derren Healthcare Private Limited became a subsidiary of the Company in compliance with SEBI (LODR) Regulations, 2015, as amended from time to time.
  6. The figures for the quarter ended March 31, 2026 as reported in these financial results, are the balancing figures between the audited figures in respect of the year ended March 31, 2026 and unaudited published nine months up to December 31, 2025.
  7. On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing Labour laws. The Ministry of Labour and Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the impact of the changes, if any, on account of the Labour Codes, draft rules and FAQs and concluded that there is no significant incremental impact in the financial results for the year ended March 31, 2026. The Company continues to monitor the finalisation of Central / State Rules and clarification.
  8. Previous period figures have been regrouped/reclassified, as considered necessary, to conform with current period presentation, wherever applicable.

*Sohan*

**Sohan Chaturvedi**  
(Whole time director & CFO)  
Genpharmasec Limited



**GENPHARMASEC LIMITED**  
**Corporate Identity Number (CIN): L24231MH1992PLC323914**  
**Statement of Standalone Audited Cash Flow**  
**(All amounts are in INR Lakhs, unless otherwise stated)**

Particulars	For the period ended March 31, 2026 (Audited)	For the period ended March 31, 2025 (Audited)
<b>A. Cash Flow From Operating Activities</b>		
Net Profit Before Tax	643.69	377.81
<b>Adjustments for:</b>		
Depreciation and Amortization	25.60	13.31
Expected Credit Loss	69.42	38.98
Interest Income other than interest on Bank Deposits	(303.88)	(543.39)
Interest on Bank Deposits	(55.78)	(77.92)
Interest on Lease Liabilities	5.37	2.55
Finance Cost other than interest on lease liabilities	53.99	25.21
Balances Written Off	0.16	-
Gratuity Expense	7.99	-
Creditors Written Back	(14.69)	-
Reversal of Excess Provision Created	(31.74)	-
Deferred rent Income	(0.53)	-
<b>Operating Profit Before Working Capital Changes</b>	<b>399.60</b>	<b>(163.45)</b>
<b>Adjustments for:</b>		
Changes in Other Non Current and Current Assets	(114.94)	117.71
Changes in Trade Receivables	(1,532.37)	(467.60)
Changes in Inventories	(533.38)	33.76
Changes in Trade Payables	2,208.74	580.73
Changes in Other Current Financial Liabilities	54.93	15.47
Changes in Other Current Liabilities	158.83	(14.20)
Changes in Other Current Financial Asset	(361.51)	(54.10)
Changes in Other Non Current Financial Assets	(5.47)	(180.81)
	<b>274.42</b>	<b>(132.49)</b>
Income Tax Paid (Net)	(81.65)	(4.31)
<b>A. Net cash flow (used in)/from operating activities</b>	<b>192.76</b>	<b>(136.80)</b>
<b>B. Cash Flow from Investing Activities</b>		
Purchase Property, Plant and Equipment	(4.25)	(0.73)
Investment made	(119.44)	(87.47)
Sale of Investment	0.06	-
Loans Given	(44.63)	(1,793.53)
Receipt against Loan Given	225.72	253.29
FD Created (Net)	(256.67)	1,104.08
Interest Received	35.04	465.39
<b>B. Net cash used in investing activities</b>	<b>(164.18)</b>	<b>(58.97)</b>
<b>C. Cash Flow from Financing Activities</b>		
Payment of Lease Liabilities	(25.82)	(12.09)
Finance Charges Paid	(53.99)	(25.21)
Proceeds/(Repayment) of Long Term Borrowings	78.11	(6.35)
<b>C. Net cash used in financing activities</b>	<b>(1.70)</b>	<b>(43.65)</b>
<b>D. Net Increase/(Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>26.88</b>	<b>(239.43)</b>
<b>E. Opening Cash &amp; Cash Equivalents (Cash and Bank Balances)</b>	<b>52.25</b>	<b>291.67</b>
<b>Closing Cash &amp; Cash Equivalents (D+E)</b>	<b>79.13</b>	<b>52.25</b>

The above Statement of Cash Flows has been prepared under 'Indirect Method' as Setout in IND AS -7 'Statement of Cash Flows'

For and on behalf of the Board of Directors of  
Genpharmasec Limited

*Sohan*

Sohan Chaturvedi  
(Whole Time Director & CFO)  
DIN : 09629728



Place: Mumbai  
Date : May 21, 2026

**Independent Auditor's Report on Consolidated Annual Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Genpharmasec Limited.**

**Opinion**

We have audited the accompanying consolidated annual financial results ('the Statement') of **Genpharmasec Limited** ('the Holding Company') and its Subsidiaries (the Holding Company and its Subsidiaries together referred to as the "the Group") for the year ended **March 31, 2026**, attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'), including relevant circulars issued by the SEBI from time to time.

In our opinion and to the best of our information and according to the explanations given to us the aforesaid consolidated annual financial results:

- include the annual financial results of the entities mentioned in Annexure I;
- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations, and
- gives a true and fair view in conformity with the applicable Indian Accounting Standards ('IndAS') prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with relevant rules issued thereunder, and other accounting principles generally accepted in India, of the consolidated net profit after tax and other comprehensive income and other financial information of the Group for the year ended March 31, 2026.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under Section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, along with the consideration of reports of other auditors referred to in sub paragraph no. (a) of the "Other Matters paragraph" below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

**Responsibilities of Management and Those Charged with Governance for the Statement**

This consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements and has been approved by the Holding Company's Board of Directors. The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation



of the consolidated annual financial results that gives a true and fair view of the consolidated net profit or loss and other comprehensive income and other financial information of the Group in accordance with the accounting principles generally accepted in India, including Ind AS prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation, and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that gives a true and fair view and is free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies included in the Group are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of each company.

#### **Auditor's Responsibilities for the Audit of the Statement**

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under Section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Group has in place adequate internal financial controls



with reference to financial statements and the operating effectiveness of such control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the management and Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Consolidated Annual Financial Results of the Company to express an opinion on the Consolidated Annual Financial Results.

Materiality is the magnitude of misstatements in the Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



### **Emphasis of Matter Paragraph**

We draw attention to the note no. 7 to the consolidated financial results regarding two subsidiaries of the Company, namely Derren Healthcare Private Limited and Clinigenome India Private Limited, which have incurred losses during the current and previous years, resulting in erosion of their net worth, and whose current liabilities exceed current assets as at the Balance Sheet date. These conditions indicate the existence of a material uncertainty that may cast significant doubt on the ability of the subsidiaries to continue as going concerns. However, the financial statements of the subsidiaries have been prepared on a going concern basis considering the management's plans for improvement in operations and continued financial support from the Holding Company and/or promoters.

Our opinion is not modified in respect of this matter.

### **Other Matter Paragraph**

- a. The consolidated annual financial results include the audited financial results of one subsidiary, whose financial results reflect total assets (before consolidation adjustments) of Rs. 2,992.08 lakhs as at 31st March 2026, total revenue (before consolidation adjustments) of Rs. 806.24 lakhs and total net loss after tax (before consolidation adjustments) of Rs.346.76 lakhs and net cash outflow (before consolidation adjustments) (net) of Rs.108.27 lakhs for the year ended on that date, as considered in the consolidated annual financial results, which has been audited by their independent auditor. The independent auditor's report on financial statements of this entity has been furnished to us by the management.

The independent auditor's report on the financial statements of this entity has been furnished to us by the Management and our opinion on the Statement in so far as it relates to the amounts and disclosures included in respect of subsidiary is based solely on the reports of such auditor and the procedures performed by us as stated in paragraph above.

- b. The accompanying Statement includes unaudited financial results and other unaudited financial information in respect of one of the subsidiaries which is located outside India have been prepared in accordance with accounting principles generally accepted in their respective countries. The Holding Company's management has converted the financial results of such subsidiary located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. The financial results and other financial information reflect total revenue of Rs. Nil, total Net loss after tax of Rs. 0.65 lakhs, total comprehensive loss of Rs. 0.65 lakhs for the year ended on that date. Our opinion in so far as it relates to the balances and affairs of such subsidiary located outside India is based on the reports of other auditors and the conversion adjustments prepared by the management of the Holding Company and audited by us.

Our opinion on the consolidated annual financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditor.



- c. We draw attention to the fact that during the year ended March 31, 2026, two subsidiaries, namely Derren Healthcare Private Limited and Clinigenome India Private Limited, are presently loss-making entities. Accordingly, the Group has carried out an impairment assessment in respect of Goodwill recognised upon acquisition of Derren Healthcare Private Limited, & treating Clinigenome Private Limited as a separate Cash Generating Unit (CGU) at the consolidated level, in accordance with Ind AS 36 - Impairment of Assets. The said assessment was carried out basis a valuation report obtained from a Registered Valuer. Based on the aforesaid valuation, the recoverable amount of the CGU exceeds it's carrying amount including Goodwill and accordingly, no impairment loss is required to be recognised as at March 31, 2026. Our opinion is not modified in respect of this matter.
- d. The consolidated annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations. Our opinion is not modified in respect of this matter.
- e. The consolidated financial results of the Company for the year ended March 31, 2025 were audited by erstwhile auditor of the Company who expressed an unmodified opinion on the consolidated financial results vide their audit report dated May 21, 2025. Our opinion is not modified in respect of this matter.

**For Bilimoria Mehta & Co.**  
Chartered Accountants  
Firm Reg. No. 101490W

*A. Mehta*



**CA Aakash Mehta**  
Partner  
Membership no. 165824  
UDIN: 26165824ECBULB7112  
Place of Signature: Mumbai  
Date: May 21, 2026

**Annexure -I**

<b>Sr No.</b>	<b>Particulars</b>	<b>Status</b>
1	Clinigenome India Private Limited	Subsidiary
2	Genpharmasec Middle East DMCC	Subsidiary
3	Derren Healthcare Private Limited	Subsidiary

Note: Derren Healthcare Private Limited has become a subsidiary company with effect from July 25, 2025.



**GENPHARMASEC LIMITED**  
**Corporate Identity Number (CIN): L24231MH1992PLC323914**  
**Statement of Consolidated Assets and Liabilities**  
**(All amounts are in INR Lakhs, unless otherwise stated)**

Particulars	As at March 31, 2026 (Audited)	As at March 31, 2025 (Audited)	As at April 01, 2024 (Audited)
<b>ASSETS</b>			
<b>(1) Non-Current Assets</b>			
(a) Property, Plant and Equipments	2,131.02	555.79	10.16
(b) Right of Use Assets	181.32	202.54	73.74
(c) Intangible Assets	0.34	-	-
(d) Goodwill	1,811.79	-	-
(e) Financial Assets			
(i) Investments	158.31	1,973.00	1,889.98
(ii) Loans	698.82	2,312.94	1,124.72
(iii) Other Financial Assets	88.55	210.14	4.50
(f) Other Non Current Assets	441.12	46.18	-
(g) Deferred Tax Assets (Net)	251.60	46.44	42.60
<b>Total Non-Current Assets</b>	<b>5,762.87</b>	<b>5,347.02</b>	<b>3,145.70</b>
<b>(2) Current Assets</b>			
(a) Inventories	1,387.53	730.45	758.19
(b) Financial Assets			
(i) Investments	-	-	168.39
(ii) Trade Receivables	2,927.10	1,359.63	909.99
(iii) Cash and Cash Equivalents	97.41	65.02	316.96
(iv) Bank Balances Other Than Cash And Cash Equivalents	909.99	462.12	1,566.20
(v) Loans	0.60	-	0.69
(vi) Other Financial Asset	96.82	0.90	-
(c) Other Current Assets	2,606.38	24.07	241.51
(d) Current Tax Asset	26.64	-	4.94
<b>Total Current Assets</b>	<b>8,052.48</b>	<b>2,642.19</b>	<b>3,966.85</b>
<b>Total Assets</b>	<b>13,815.35</b>	<b>7,989.21</b>	<b>7,112.55</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
(a) Equity Share Capital	5,537.20	5,537.20	5,537.20
(b) Other Equity	1,089.27	979.11	902.33
(c) Non- Controlling Interest	(61.98)	11.65	13.95
<b>Total Equity</b>	<b>6,564.49</b>	<b>6,527.95</b>	<b>6,453.48</b>
<b>LIABILITIES</b>			
<b>(1) Non-Current Liabilities</b>			
(a) Financial Liabilities			
(i) Borrowings	2,397.24	314.69	321.04
(ii) Lease Liabilities	136.77	161.97	67.83
(iii) Provisions	13.91	1.04	-
<b>Total Non-Current Liabilities</b>	<b>2,547.93</b>	<b>477.70</b>	<b>388.87</b>
<b>(2) Current Liabilities</b>			
(a) Financial Liabilities			
(i) Borrowings	900.45	-	-
(ii) Lease Liabilities	60.22	51.79	-
(iii) Trade Payables			
(A) Total outstanding dues of micro and small enterprises	40.57	16.64	11.73
(B) Total outstanding dues of creditors other than micro and small enterprises	3,118.12	809.25	226.16
(iv) Other Financial Liabilities	292.76	15.46	-
(b) Short Term Provisions	2.67	0.00	-
(c) Current Tax Liabilities (net)	91.22	56.41	-
(d) Other Current Liabilities	196.93	34.00	32.31
<b>Total Current Liabilities</b>	<b>4,702.93</b>	<b>983.56</b>	<b>270.20</b>
<b>Total Equity and Liabilities</b>	<b>13,815.35</b>	<b>7,989.21</b>	<b>7,112.55</b>

For and on behalf of the Board of Directors of  
Genpharmasec Limited

*Sohan*

Sohan Chaturvedi  
(Whole Time Director & CFO)  
DIN : 09629728



Place: Mumbai  
Date: May 21, 2026

**GENPHARMASEC LIMITED**

Corporate Identity Number (CIN): L24231MH1992PLC323914

Statement of Consolidated Audited Financial Results for the Quarter and Year Ended March 31, 2026

(All amounts are in INR Lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31st March 2026	31st December 2025	31st March 2025	31st March 2026	31st March 2025
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from Operations	5,542.92	3,982.81	1,400.97	13,993.77	3,372.18
II	Other Income	101.57	98.18	93.68	315.70	306.22
III	<b>Total Income (I+II)</b>	<b>5,644.49</b>	<b>4,080.99</b>	<b>1,494.65</b>	<b>14,309.47</b>	<b>3,678.40</b>
IV	<b>Expenses</b>					
	Cost of materials consumed	12.32	170.07	37.94	284.02	87.21
	Purchase of Stock-in-Trade	4,654.89	3,384.96	1,002.40	13,139.94	2,960.22
	Changes in Inventories of Finished goods, Stock-in-Trade and Work-in-progress	347.02	220.30	410.15	(565.96)	27.74
	Employee Benefit Expenses	106.87	125.45	31.03	387.00	99.91
	Finance Costs	48.11	41.14	10.64	124.03	43.48
	Depreciation and Amortization Expense	67.53	66.50	25.65	216.84	81.15
	Other Expenses	222.47	205.80	20.72	626.54	157.52
	<b>Total Expenses (IV)</b>	<b>5,459.21</b>	<b>4,214.21</b>	<b>1,538.52</b>	<b>14,212.40</b>	<b>3,457.22</b>
V	<b>Profit before Tax ( III- IV )</b>	<b>185.28</b>	<b>(133.22)</b>	<b>(43.87)</b>	<b>97.07</b>	<b>221.18</b>
VI	<b>Tax Expense :</b>					
	(1) Current Period	62.80	15.83	25.53	152.32	68.74
	(2) Deferred Tax	(12.82)	(30.00)	(10.04)	(75.40)	(3.84)
	(3) Prior Period Tax	-	(35.86)	-	(35.86)	-
	<b>Total Tax Expense</b>	<b>49.98</b>	<b>(50.03)</b>	<b>15.49</b>	<b>41.06</b>	<b>64.90</b>
VII	<b>Profit for the period ( V -VI )</b>	<b>135.30</b>	<b>(83.19)</b>	<b>(28.38)</b>	<b>56.01</b>	<b>156.28</b>
	<b>Profit/(loss) Attributable to</b>					
	i. Equity Holder of Parent	122.58	(43.12)	(28.38)	160.33	158.60
	ii. Non Controlling Interest	12.72	(40.07)	(0.00)	(104.32)	(2.32)
VIII	<b>Other Comprehensive Income</b>					
	A (i) Item that will not be reclassified to profit or loss					
	(a) Remeasurement of post employment defined benefit plans	-	-	-	0.68	-
	(b) Income tax effect on above	-	-	-	(0.17)	-
	(c) Equity instrument through other comprehensive income	(40.65)	(6.22)	(45.41)	(50.68)	(81.81)
	(d) Income tax effect on above	-	-	-	-	-
	<b>Sub-total</b>	<b>(40.65)</b>	<b>(6.22)</b>	<b>(45.41)</b>	<b>(50.17)</b>	<b>(81.81)</b>
IX	<b>Total Comprehensive Income for the period (VII + VIII)</b> <b>(Comprising profit and other comprehensive income for the year)</b>	<b>94.65</b>	<b>(89.42)</b>	<b>(73.79)</b>	<b>5.84</b>	<b>74.47</b>
	<b>Total Comprehensive Income/(Loss) Attributable to</b>					
	i. Equity Holder of Parent	(107.88)	(49.34)	(73.79)	110.16	76.79
	ii. Non Controlling Interest	12.72	(40.07)	(0.00)	(104.32)	(2.32)
	<b>Paid up Equity Share Capital ( Face Value of Equity Share is Rs. 1/- each )</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>
	<b>Other Equity</b>					<b>990.77</b>
X	<b>Earnings per equity share:</b>					
	(1) Basic	0.02	(0.02)	(0.01)	0.01	0.03
	(2) Diluted	0.02	(0.02)	(0.01)	0.01	0.03

For and on behalf of the Board of Directors of  
Genpharmasec Limited

*Sohan*

Sohan Chaturvedi  
(Whole Time Director & CFO)  
DIN : 09629728



Place: Mumbai  
Date: May 21, 2026

## Notes to consolidated audited financial results for the quarter and year ended March 31, 2026

1. The consolidated audited financial results of the Company for the quarter and year ended March 31, 2026 have been prepared in accordance with the Indian Accounting Standards ("Indian Accounting Standards ("Ind As") As Prescribed under section 133 of the Companies Act, 2013 as amended.
2. Segment Reporting has been annexed in Annexure 1.
3. The consolidated audited financial results of the Company for the quarter and year ended March 31, 2026 have been reviewed by the audit committee on May 21, 2026 and thereafter Board of directors at their meeting held on May 21, 2026.
4. During the financial year, the Holding Company reviewed its accounting policy relating to the classification and measurement of certain equity shares that were previously presented under Inventories. Upon a detailed evaluation of the nature and purpose of holding these shares, the management concluded that these instruments are held for investment purposes rather than for trading in the ordinary course of business.

Accordingly, during the current year, the Holding Company has reclassified such shares from Inventories to Financial Investments in accordance with the requirements of Ind AS 109 - Financial Instruments and Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors. Consequently, these financial instruments are now measured at fair value through other comprehensive income (FVOCI) instead of being measured at the lower of cost and net realizable value under Ind AS 2 - Inventories.

The change in accounting policy has been applied retrospectively, and the financial impact of this reclassification for the period ended March 31, 2026, is as follows:

1. Decrease in Inventories: Rs. 89.32 Lakhs
  2. Increase in Investment (before impact of Fair value): Rs. 89.32 Lakhs
  3. Net Impact on Profit Before Tax: Nil
  4. Net impact on total comprehensive income: Rs. (22.66) Lakhs
5. During the year ended March 31, 2024, the Holding Company entered into a Share Purchase Agreement (SPA) and a Share Subscription-cum-Shareholders Agreement (SSSA) on September 19, 2023 with M/s. Derren Healthcare Private Limited and its promoters for acquiring a 70% stake. The acquisition was completed on July 25, 2025, and accordingly, Derren Healthcare Private Limited became a subsidiary of the Company in compliance with SEBI (LODR) Regulations, 2015, as amended from time to time.
  6. The figures for the quarter ended March 31, 2026 as reported in these financial results, are the balancing figures between the audited figures in respect of the year ended March 31, 2026 and unaudited published nine months up to December 31, 2025.
  7. Two subsidiaries of the Company, namely Derren Healthcare Private Limited and Clinigenome India Private Limited (collectively referred to as "the Subsidiaries"), have incurred losses during the current year as well as the previous year. As at the Balance Sheet date, the accumulated losses of the Subsidiaries have resulted in a complete erosion of their respective net worth. Furthermore, the current liabilities of the Subsidiaries continue to exceed their current assets as at both the current and previous year Balance Sheet dates.

The aforesaid conditions indicate the existence of a material uncertainty that may cast significant doubt on the ability of the Subsidiaries to continue as going concerns and, therefore, they may be unable to realise their assets and discharge their liabilities in the normal course of business.


Notwithstanding the above, the financial statements of the Subsidiaries have been prepared on a going concern basis. In arriving at this conclusion, the management has taken into account the following factors:

- (a) The management has drawn up plans to improve the operational performance of the Subsidiaries, including measures to enhance revenues and rationalise and reduce costs;
- (b) The Holding Company and/or the promoters have confirmed their intention and ability to provide the necessary financial support to the Subsidiaries to enable them to meet their financial obligations as and when they fall due; and
- (c) Based on the expected future cash flows of the Subsidiaries and the committed financial support from the Holding Company and/or promoters, the management is of the view that the Subsidiaries will be in a position to generate adequate returns and meet their liabilities in the normal course of business.



Based on the foregoing, the management believes that the going concern basis of accounting is appropriate for the preparation of the financial statements of the Subsidiaries and that no adjustments are required to the carrying values of assets and liabilities as at the Balance Sheet date.

8. On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing Labour laws. The Ministry of Labour and Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the impact of the changes, if any, on account of the Labour Codes, draft rules and FAQs and concluded that there is no significant incremental impact in the financial results for the year ended March 31, 2026. The Company continues to monitor the finalisation of Central / State Rules and clarification.
9. Previous period figures have been regrouped/reclassified, as considered necessary, to conform with current period presentation, wherever applicable.



**Sohan Chaturvedi**

(Whole time director & CFO)

**Genpharmasec Limited**



**GENPHARMASEC LIMITED**  
**Corporate Identity Number (CIN): L24231MH1992PLC323914**  
**Statement of Consolidated Audited Cash Flow**  
**(All amounts are in INR Lakhs, unless otherwise stated)**

Particulars	For the period ended March 31, 2026 (Audited)	For the period ended March 31, 2025 (Audited)
<b>A. Cash Flow From Operating Activities</b>		
<b>Net Profit Before Tax</b>	97.07	221.18
<b>Adjustments for:</b>		
Depreciation	216.84	81.15
Expected Credit Loss	69.42	39.40
Interest Income other than interest on Bank Deposits	(112.22)	(228.30)
Interest on Bank Deposits	(56.98)	(77.92)
Interest on Lease Liabilities	19.28	18.24
Finance Cost other than interest on lease liabilities	104.75	62.58
Balances Written Off	0.16	-
Gratuity Expense	11.72	1.04
Creditors Written Back	(23.73)	-
Reversal of Excess Provision Created	(32.78)	-
Deferred rent Income	(1.54)	-
Profit on derecognition of Liability	(3.21)	-
Loss on derecognition of Financial Asset	4.73	-
<b>Operating Profit Before Working Capital Changes</b>	<b>293.49</b>	<b>117.37</b>
<b>Adjustments for:</b>		
Changes in Other Non Current and Current Assets	(2,096.76)	169.87
Changes in Trade Receivables	(1,534.65)	(489.04)
Changes in Inventories	(571.79)	27.74
Changes in Trade Payables	2,290.71	588.00
Changes in Other Non Current Financial Liabilities	(0.84)	0.01
Changes in Other Current Financial Liabilities	(76.06)	15.46
Changes in Other Current Liabilities	118.40	1.69
Changes in Other Current Financial Asset	(214.10)	(0.90)
Changes in Other Non Current Financial Assets	135.68	(127.72)
	<b>(1,655.92)</b>	<b>302.48</b>
Income Tax Paid (Net)	(99.30)	(7.40)
<b>A. Net cash flow (used in)/from operating activities</b>	<b>(1,755.21)</b>	<b>295.09</b>
<b>B. Cash Flow from Investing Activities</b>		
Purchase Property, Plant and Equipment	(52.09)	(570.52)
Purchase of Investments	(104.90)	3.56
Sale of Investment	0.06	-
Loans Given	1,497.31	(1,440.82)
Receipt against Loan Given	225.72	253.29
FD Created	(316.66)	1,104.08
Interest Received	19.91	195.20
Other Interest Received	56.98	33.10
<b>B. Net cash used in investing activities</b>	<b>1,326.32</b>	<b>(422.12)</b>
<b>C. Cash Flow from Financing Activities</b>		
Payment of Lease Liabilities	(72.65)	(55.97)
Finance Charges Paid	(104.75)	(62.58)
Proceeds/(Repayment) of Long Term Borrowings (Net)	569.54	(6.35)
<b>C. Net Cash from Financing Activities</b>	<b>392.14</b>	<b>(124.90)</b>
<b>D. Net Increase/(Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(36.76)</b>	<b>(251.94)</b>
Cash & cash equivalents acquired pursuant to acquisition of subsidiary	69.14	-
<b>E. Opening Cash &amp; Cash Equivalents (Cash and Bank Balances)</b>	<b>65.02</b>	<b>316.96</b>
<b>Closing Cash &amp; Cash Equivalents (D+E)</b>	<b>97.41</b>	<b>65.02</b>

The above Statement of Cash Flows has been prepared under 'Indirect Method' as set out in IND AS -7 'Statement of Cash Flows'

For and on behalf of the Board of Directors of  
Genpharmasec Limited

*Sohan*

Sohan Chaturvedi  
(Whole Time Director & CFO)  
DIN : 09629728



Place: Mumbai  
Date: May 21, 2026

**GENPHARMASEC LIMITED**  
Corporate Identity Number (CIN): L24231MH1992PLC323914  
"ANNEXURE - 1"

**Statement of Consolidated audited Segment-wise Revenue, Results, Assets and Liabilities for the Quarter and Year ended March 31, 2026**  
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	Quarter Ended			Year Ended	
	31st March 2026	31st December 2025	31st March 2025	31st March 2026	31st March 2025
	Audited	Unaudited	Audited	Audited	Audited
<b>Segment Revenue</b>					
Pharmaceuticals	5,166.43	3,681.83	1,329.50	13,087.05	3,255.86
Laboratory Testing	-	22.18	71.46	100.47	116.32
Manufacturing & Processing	376.49	278.79	-	806.24	-
Unallocable	-	-	-	-	-
<b>Total Revenue</b>	<b>5,542.92</b>	<b>3,982.81</b>	<b>1,400.97</b>	<b>13,993.77</b>	<b>3,372.18</b>
<b>Segment Results (Profit before tax and interest)</b>					
Pharmaceuticals	311.02	67.86	2.43	703.05	405.56
Laboratory Testing	(43.94)	(35.97)	(34.38)	(158.87)	(136.09)
Manufacturing & Processing	(33.14)	(123.95)	-	(322.44)	-
Unallocable	(0.56)	(0.01)	(1.29)	(0.65)	(4.81)
<b>Total</b>	<b>233.39</b>	<b>(92.08)</b>	<b>(33.24)</b>	<b>221.09</b>	<b>264.67</b>
<b>Less</b>					
(i) Unallocated Finance Cost	(48.11)	(41.14)	(10.64)	(124.03)	(43.48)
(ii) Other unallowable expenditure net of unallowable income	-	-	-	-	-
(iii) Inter Segment Eliminations	-	-	-	-	-
<b>Profit Before Tax</b>	<b>185.28</b>	<b>(133.22)</b>	<b>(43.87)</b>	<b>97.07</b>	<b>221.18</b>
<b>Segment Assets</b>					
Pharmaceuticals	6,189.42	6,102.80	2,329.91	6,189.42	2,329.91
Laboratory Testing	753.26	806.81	880.59	753.26	880.59
Manufacturing & Processing	2,992.08	2,158.59	-	2,992.08	-
Unallocated	3,880.58	1,827.82	4,778.71	3,880.58	4,778.71
<b>Total</b>	<b>13,815.34</b>	<b>10,896.02</b>	<b>7,989.21</b>	<b>13,815.34</b>	<b>7,989.21</b>
<b>Segment Liabilities</b>					
Pharmaceuticals	3,856.43	3,842.76	1,365.18	3,856.43	1,365.18
Laboratory Testing	136.85	156.30	96.09	136.85	96.09
Manufacturing & Processing	1,194.37	417.97	-	1,194.37	-
Unallocated	2,063.22	9.56	-	2,063.22	-
<b>Total</b>	<b>7,250.86</b>	<b>4,426.59</b>	<b>1,461.27</b>	<b>7,250.86</b>	<b>1,461.27</b>

The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments" (IND AS 108).

For and on behalf of the Board of Directors of  
Genpharmasec Limited

*Soham*

Soham Chaturvedi  
(Whole Time Director & CFO)  
DIN : 09629728



Place: Mumbai  
Date: May 21, 2026